Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland
Authors' conclusion
Oral semaglutide significantly improves glycaemic and lipid control, body weight, and liver enzymes in adults living with T2D treated in clinical practice.
Study context
- Population
- Adults with T2D naïve to any GLP-1 RA, initiating oral semaglutide April 1, 2021–December 31, 2023, identified from Finnish national registers, followed until June 30, 2024
- Participants
- 7,249 adults
- Outcome
- Changes in HbA1c and body weight from baseline
- Follow-up
- 182.5 and 365 days
Methodological detailsnationwide, real-world, register-based
- Nationwide
- Real-world
- Register-based
Main finding
As reported in the abstract
Mean HbA1c (n = 2784), baseline to 182.5 days
7.9% to 6.8%
95% CI −1.20 to −1.04p < 0.001
Mean HbA1c (n = 2784), baseline to 365 days
7.9% to 6.9%
95% CI −1.18 to −0.95p < 0.001
Mean body weight (n = 832), baseline to 182.5 days
106 to 100 kg
95% CI −7 to −5p < 0.001
Mean body weight (n = 832), baseline to 365 days
106 to 98 kg
95% CI −10 to −6p < 0.001
Observational data: associations, not effects.
Secondary outcomes
Treatment persistence
- Remained on treatment at 180 days
- 65.8%
- Remained on treatment at 365 days
- 55.2%
LDL-C (n = 1402) and TG (n = 975) · 182.5 and 365 days
- Significantly reduced at 182.5 days with little further change at 365 days
Mean ALT (n = 1762) · 182.5 and 365 days
- Baseline to 182.5 days
- 50 to 42 U/L (95% CI: −10 to −6, p < 0.001)
- Baseline to 365 days
- 50 to 37 U/L (95% CI: −16 to −10; p < 0.001)
HbA1c and weight changes by age (≥75 vs <75 years)
- Baseline weight lower in patients aged ≥75 years; changes in HbA1c and weight similar to patients <75 years
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →